保留
发表于 2025-3-28 17:54:40
Mitral Valve,erature and varies greatly between studies. In general, younger patients (less than 65 years of age) have much higher rates of SVD compared to their older counterparts and reoperation more frequently. A number of publications have done subgroup analysis to determine the effect of age at time of surg
离开就切除
发表于 2025-3-28 18:51:26
http://reply.papertrans.cn/23/2226/222573/222573_42.png
高兴一回
发表于 2025-3-29 02:55:07
Cost-Effectiveness of Transcatheter Aortic Valve Replacement,value of these therapies. TAVR, along with other transcatheter valve therapies, is no exception, and cost-effectiveness for their use in a broad population must be fully understood and appropriateness criteria applied in a patient-centric manner.
intrude
发表于 2025-3-29 03:29:53
Challenges in Valve-in-Valve Therapy for Aortic Valves,oronary occlusion, embolization, and thrombosis have been reported. We aim to discuss relevant features of the different surgical and transcatheter devices and discuss the optimal strategy to avoid these complications after a VIV procedure.
尊重
发表于 2025-3-29 10:07:10
Book 2016ry, and ascending arch stent repair are highlighted...Catheter Based Valve and Aortic Surgery. will be a useful tool for cardiac and vascular surgeons, interventional cardiologists, general cardiologists, and clinicians and researchers with an interest in these exciting new developments in structural heart and vascular diseases..
engrossed
发表于 2025-3-29 14:02:04
http://reply.papertrans.cn/23/2226/222573/222573_46.png
patriot
发表于 2025-3-29 18:04:14
Small Increments of a Trajectory is increasingly utilized, the transapical approach is an indispensable part of the surgeon’s armamentarium for difficult-access patients. Moreover, since future transcatheter interventions will likely utilize the transapical approach, it is incumbent on cardiac surgeons to become facile with this exposure.
Urea508
发表于 2025-3-29 21:32:05
J. Ryan Martin MD,Rafael J. Sierra MDwith FMR do benefit from MitraClip placement with durable reduction in MR and symptomatic relief. Data from European registries and results of the ongoing COAPT trial in US patients may better inform which FMR patients are most likely to benefit from MitraClip placement.
欢呼
发表于 2025-3-30 03:34:39
https://doi.org/10.1007/978-3-319-50749-1y, and most important with calcific stenosis a secure landing spot for transcatheter valve anchorage. However, with transcatheter valve technology improving rapidly, nonsurgical and high-risk surgical patients with mitral regurgitation now have the option to have a transcatheter mitral valve repair.
Gentry
发表于 2025-3-30 07:23:24
http://reply.papertrans.cn/23/2226/222573/222573_50.png